Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Syndax Pharmaceuticals Inc(SNDX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SNDX
10/14/2026: SNDX (1-star) is currently NOT-A-BUY. Pass it for now.
Syndax Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative oncology therapies, recently achieving a major milestone with the FDA approval of its first drug, Niktimvo. The company’s primary strength lies in its specialized pipeline targeting complex cancers like leukemia and graft-versus-host disease. Its key investment narrative centers on transitioning into a commercial-stage firm while advancing late-stage clinical assets. Risks include the high operational costs associated with drug development, intense competition from well-capitalized firms, and the inherent execution challenges of a new commercial launch. This stock may suit growth-oriented investors capable of managing the volatility typical of clinical-stage biotechnology firms.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company offers exposure to high-growth potential in the oncology market through late-stage clinical and new commercial assets. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may favor the stock during periods of positive clinical data readouts or regulatory approval catalysts. |
| Value investor | Weak fit | As a loss-making biotech firm, the company lacks the consistent earnings required for traditional value-based investment strategies. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on growth capital expenditure. |
| Low-risk investor | Weak fit | The biotechnology sector entails high volatility and clinical success risks unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical results and regulatory decisions can lead to sharp fluctuations in share price. |
| Valuation risk | Medium / high | Valuations are often speculative, based on future peak sales potential rather than current profits. |
| Competition risk (Oncology/Hematology) | High | Large incumbents can rapidly pivot or acquire new technology, threatening the market share of smaller players. |
| Business quality | Medium | The company is evolving from an R&D shop to a commercial player, which is an inherently challenging operational shift. |
| Dividend income | Low / none | There is no income component to the investment thesis. |
| Execution risk | High | Success depends on the complex execution of commercial launch strategies and future regulatory approvals. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -7.87% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.25B USD | Price to earnings Ratio - | 1Y Target Price 37.27 |
Price to earnings Ratio - | 1Y Target Price 37.27 | ||
Volume (30-day avg) 2.0M shares | Beta 0.42 | 52 Weeks Range 12.99 - 25.59 | Updated Date 10/14/2026 |
52 Weeks Range 12.99 - 25.59 | Updated Date 10/14/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.52 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology Therapeutics | Commercial revenue from Niktimvo and potential future licensing or product sales from Revumenib. | The company generates cash by selling specialty drugs to treat cancer, with future revenue dependent on the success of its drug pipeline. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1.61B | Price to Sales(TTM) 4.94 |
Enterprise Value 1.61B | Price to Sales(TTM) 4.94 | ||
Enterprise Value to Revenue 6.38 | Enterprise Value to EBITDA -105.26 | Shares Outstanding 89.30M | Shares Floating 80.30M |
Shares Outstanding 89.30M | Shares Floating 80.30M | ||
Percent Insiders 1.69 | Percent Institutions 126.04 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.